education
Download App
Indonesia
search
Masuk
Home
Find Drugs
Pill Identifier
Find Drug Company
Diseases
Medical News & Updates
Country
Hong Kong
India
Indonesia
Malaysia
Philippines
Singapore
Thailand
Vietnam
Australia
Korea
New Zealand
search
UserName
Profession
Email
Account
Manage Account
Change Password
Sign Out
Home
Find Drugs
Pill Identifier
Find Drug Company
Diseases
Medical News & Updates
Other Services
Education
Download App
Country
Indonesia
Hong Kong
India
Indonesia
Malaysia
Philippines
Singapore
Thailand
Vietnam
Australia
Korea
New Zealand
Account
Masuk
Home
Find Drugs
Pill Identifier
Find Drug Company
Diseases
Medical News & Updates
Iklan
Iklan
MIMS home
Drugs
Info
Farnormin
Farnormin
atenolol
Manufacturer:
Fahrenheit
SELECT
Concise Prescribing Info
Bahasa Concise Prescribing Info
Concise Prescribing Info
Bahasa Concise Prescribing Info
Concise Prescribing Info
Contents
Atenolol
Indications/Uses
HTN. Angina pectoris.
Dosage/Direction for Use
Adult
HTN
50 mg daily, increase to 100 mg daily after 2 wk if required.
Angina pectoris
100 mg daily.
Administration
May be taken with or without food.
Contraindications
2nd or 3rd degree AV block, overt cardiac failure, bronchial asthma, cardiogenic shock. Sinus bradycardia.
Special Precautions
CHF, renal dysfunction, DM, hypoglycemia; surgery, anesth; concurrent use of verapamil. Pregnancy.
Adverse Reactions
Headache, vertigo, tiredness, weakness, sedation, depression; bradycardia, postural hypotension; cold extremities; GI upsets; bronchospasm.
View
ADR Reporting Link
Drug Interactions
Clonidine, digitalis glycosides, sympathomimetics. Non-depolarising blockers.
MIMS Class
Beta-Blockers
ATC Classification
C07AB03 - atenolol ; Belongs to the class of selective beta-blocking agents. Used in the treatment of cardiovascular diseases.
Regulatory Classification
K
Presentation/Packing
Form
Farnormin tab 50 mg
Packing/Price
100's (Rp40,000/pak)
Iklan
Iklan
Iklan
Iklan
Iklan
Iklan
Iklan
Daftar Gratis untuk melanjutkan membaca
Lanjutkan dengan Google
Daftar dengan email
Sudah punya akun?
Masuk
Daftar Gratis untuk melanjutkan membaca
Lanjutkan dengan Google
Daftar dengan email
Sudah punya akun?
Masuk